Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy: Which Threshold Is the Best Predictor of Local Control?

PURPOSEIn the context of oropharyngeal cancer treated with definitive radiotherapy, the aim of this retrospective study was to identify the best threshold value to compute metabolic tumor volume (MTV) and/or total lesion glycolysis to predict local-regional control (LRC) and disease-free survival. M...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical nuclear medicine 2017-06, Vol.42 (6), p.e281-e285
Hauptverfasser: Castelli, Joël, Depeursinge, Adrien, de Bari, Berardino, Devillers, Anne, de Crevoisier, Renaud, Bourhis, Jean, Prior, John O
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e285
container_issue 6
container_start_page e281
container_title Clinical nuclear medicine
container_volume 42
creator Castelli, Joël
Depeursinge, Adrien
de Bari, Berardino
Devillers, Anne
de Crevoisier, Renaud
Bourhis, Jean
Prior, John O
description PURPOSEIn the context of oropharyngeal cancer treated with definitive radiotherapy, the aim of this retrospective study was to identify the best threshold value to compute metabolic tumor volume (MTV) and/or total lesion glycolysis to predict local-regional control (LRC) and disease-free survival. METHODSOne hundred twenty patients with a locally advanced oropharyngeal cancer from 2 different institutions treated with definitive radiotherapy underwent FDG PET/CT before treatment. Various MTVs and total lesion glycolysis were defined based on 2 segmentation methods(i) an absolute threshold of SUV (0–20 g/mL) or (ii) a relative threshold for SUVmax (0%–100%). The parameters’ predictive capabilities for disease-free survival and LRC were assessed using the Harrell C-index and Cox regression model. RESULTSRelative thresholds between 40% and 68% and absolute threshold between 5.5 and 7 had a similar predictive value for LRC (C-index = 0.65 and 0.64, respectively). Metabolic tumor volume had a higher predictive value than gross tumor volume (C-index = 0.61) and SUVmax (C-index = 0.54). Metabolic tumor volume computed with a relative threshold of 51% of SUVmax was the best predictor of disease-free survival (hazard ratio, 1.23 [per 10 mL], P = 0.009) and LRC (hazard ratio1.22 [per 10 mL], P = 0.02). CONCLUSIONSThe use of different thresholds within a reasonable range (between 5.5 and 7 for an absolute threshold and between 40% and 68% for a relative threshold) seems to have no major impact on the predictive value of MTV. This parameter may be used to identify patient with a high risk of recurrence and who may benefit from treatment intensification.
doi_str_mv 10.1097/RLU.0000000000001614
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01534147v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1877526678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3394-dd7674512343d1427cb825d167c279a7d88850a56f5f0cb39c11380633acd7253</originalsourceid><addsrcrecordid>eNp9kd9uFCEUhydGY7fVNzCGS72Yyp8ZYLwxda1tkzE1zdReEhYYQdlhBabNvpGPKevWxnghNyTwnd_h8FXVCwSPEezYm6v--hj-tRBFzaNqgVpCa4hx97haQEJJ3TGKD6rDlL79ZmjztDrAHHMOG7yofn4yWa6CdwoM8zpE8CX4eW2AnDQYQpYe9Ca5MIEzv1XBb5NLwE3gMoaNlXE7fTUFWcpJmQiGaGQ2Gty4bMEHM7rJZXdrwJXULmRrotxs34Ib65QFg40m2eA1uEig3IH3JmXwORrtVC7PCCPog9plhynH4N89q56M0ifz_H4_qq4_ng7L87q_PLtYnvS1IqRraq0ZZU2LMGmIRg1masVxqxFlCrNOMs05b6Fs6diOUK1IpxAiHFJCpNIMt-Soer3PtdKLTXTrMqUI0onzk17szmD54QY17BYV9tWe3cTwYy4DiLVLyngvJxPmJBBnrMWUMl7QZo-qGFKKZnzIRlDsfIriU_zrs5S9vO8wr9ZGPxT9EVgAvgfugs8mpu9-vjNR2KIl2_9n_wJREqxt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1877526678</pqid></control><display><type>article</type><title>Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy: Which Threshold Is the Best Predictor of Local Control?</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Castelli, Joël ; Depeursinge, Adrien ; de Bari, Berardino ; Devillers, Anne ; de Crevoisier, Renaud ; Bourhis, Jean ; Prior, John O</creator><creatorcontrib>Castelli, Joël ; Depeursinge, Adrien ; de Bari, Berardino ; Devillers, Anne ; de Crevoisier, Renaud ; Bourhis, Jean ; Prior, John O</creatorcontrib><description>PURPOSEIn the context of oropharyngeal cancer treated with definitive radiotherapy, the aim of this retrospective study was to identify the best threshold value to compute metabolic tumor volume (MTV) and/or total lesion glycolysis to predict local-regional control (LRC) and disease-free survival. METHODSOne hundred twenty patients with a locally advanced oropharyngeal cancer from 2 different institutions treated with definitive radiotherapy underwent FDG PET/CT before treatment. Various MTVs and total lesion glycolysis were defined based on 2 segmentation methods(i) an absolute threshold of SUV (0–20 g/mL) or (ii) a relative threshold for SUVmax (0%–100%). The parameters’ predictive capabilities for disease-free survival and LRC were assessed using the Harrell C-index and Cox regression model. RESULTSRelative thresholds between 40% and 68% and absolute threshold between 5.5 and 7 had a similar predictive value for LRC (C-index = 0.65 and 0.64, respectively). Metabolic tumor volume had a higher predictive value than gross tumor volume (C-index = 0.61) and SUVmax (C-index = 0.54). Metabolic tumor volume computed with a relative threshold of 51% of SUVmax was the best predictor of disease-free survival (hazard ratio, 1.23 [per 10 mL], P = 0.009) and LRC (hazard ratio1.22 [per 10 mL], P = 0.02). CONCLUSIONSThe use of different thresholds within a reasonable range (between 5.5 and 7 for an absolute threshold and between 40% and 68% for a relative threshold) seems to have no major impact on the predictive value of MTV. This parameter may be used to identify patient with a high risk of recurrence and who may benefit from treatment intensification.</description><identifier>ISSN: 0363-9762</identifier><identifier>EISSN: 1536-0229</identifier><identifier>DOI: 10.1097/RLU.0000000000001614</identifier><identifier>PMID: 28288042</identifier><language>eng</language><publisher>United States: Copyright Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Adult ; Aged ; Bioengineering ; Disease-Free Survival ; Female ; Fluorodeoxyglucose F18 - metabolism ; Glycolysis ; Humans ; Life Sciences ; Male ; Middle Aged ; Oropharyngeal Neoplasms - diagnostic imaging ; Oropharyngeal Neoplasms - metabolism ; Oropharyngeal Neoplasms - pathology ; Oropharyngeal Neoplasms - radiotherapy ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography ; Proportional Hazards Models ; Retrospective Studies ; Tumor Burden</subject><ispartof>Clinical nuclear medicine, 2017-06, Vol.42 (6), p.e281-e285</ispartof><rights>Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3394-dd7674512343d1427cb825d167c279a7d88850a56f5f0cb39c11380633acd7253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28288042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://univ-rennes.hal.science/hal-01534147$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Castelli, Joël</creatorcontrib><creatorcontrib>Depeursinge, Adrien</creatorcontrib><creatorcontrib>de Bari, Berardino</creatorcontrib><creatorcontrib>Devillers, Anne</creatorcontrib><creatorcontrib>de Crevoisier, Renaud</creatorcontrib><creatorcontrib>Bourhis, Jean</creatorcontrib><creatorcontrib>Prior, John O</creatorcontrib><title>Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy: Which Threshold Is the Best Predictor of Local Control?</title><title>Clinical nuclear medicine</title><addtitle>Clin Nucl Med</addtitle><description>PURPOSEIn the context of oropharyngeal cancer treated with definitive radiotherapy, the aim of this retrospective study was to identify the best threshold value to compute metabolic tumor volume (MTV) and/or total lesion glycolysis to predict local-regional control (LRC) and disease-free survival. METHODSOne hundred twenty patients with a locally advanced oropharyngeal cancer from 2 different institutions treated with definitive radiotherapy underwent FDG PET/CT before treatment. Various MTVs and total lesion glycolysis were defined based on 2 segmentation methods(i) an absolute threshold of SUV (0–20 g/mL) or (ii) a relative threshold for SUVmax (0%–100%). The parameters’ predictive capabilities for disease-free survival and LRC were assessed using the Harrell C-index and Cox regression model. RESULTSRelative thresholds between 40% and 68% and absolute threshold between 5.5 and 7 had a similar predictive value for LRC (C-index = 0.65 and 0.64, respectively). Metabolic tumor volume had a higher predictive value than gross tumor volume (C-index = 0.61) and SUVmax (C-index = 0.54). Metabolic tumor volume computed with a relative threshold of 51% of SUVmax was the best predictor of disease-free survival (hazard ratio, 1.23 [per 10 mL], P = 0.009) and LRC (hazard ratio1.22 [per 10 mL], P = 0.02). CONCLUSIONSThe use of different thresholds within a reasonable range (between 5.5 and 7 for an absolute threshold and between 40% and 68% for a relative threshold) seems to have no major impact on the predictive value of MTV. This parameter may be used to identify patient with a high risk of recurrence and who may benefit from treatment intensification.</description><subject>Adult</subject><subject>Aged</subject><subject>Bioengineering</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18 - metabolism</subject><subject>Glycolysis</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oropharyngeal Neoplasms - diagnostic imaging</subject><subject>Oropharyngeal Neoplasms - metabolism</subject><subject>Oropharyngeal Neoplasms - pathology</subject><subject>Oropharyngeal Neoplasms - radiotherapy</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Positron-Emission Tomography</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Tumor Burden</subject><issn>0363-9762</issn><issn>1536-0229</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kd9uFCEUhydGY7fVNzCGS72Yyp8ZYLwxda1tkzE1zdReEhYYQdlhBabNvpGPKevWxnghNyTwnd_h8FXVCwSPEezYm6v--hj-tRBFzaNqgVpCa4hx97haQEJJ3TGKD6rDlL79ZmjztDrAHHMOG7yofn4yWa6CdwoM8zpE8CX4eW2AnDQYQpYe9Ca5MIEzv1XBb5NLwE3gMoaNlXE7fTUFWcpJmQiGaGQ2Gty4bMEHM7rJZXdrwJXULmRrotxs34Ib65QFg40m2eA1uEig3IH3JmXwORrtVC7PCCPog9plhynH4N89q56M0ifz_H4_qq4_ng7L87q_PLtYnvS1IqRraq0ZZU2LMGmIRg1masVxqxFlCrNOMs05b6Fs6diOUK1IpxAiHFJCpNIMt-Soer3PtdKLTXTrMqUI0onzk17szmD54QY17BYV9tWe3cTwYy4DiLVLyngvJxPmJBBnrMWUMl7QZo-qGFKKZnzIRlDsfIriU_zrs5S9vO8wr9ZGPxT9EVgAvgfugs8mpu9-vjNR2KIl2_9n_wJREqxt</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Castelli, Joël</creator><creator>Depeursinge, Adrien</creator><creator>de Bari, Berardino</creator><creator>Devillers, Anne</creator><creator>de Crevoisier, Renaud</creator><creator>Bourhis, Jean</creator><creator>Prior, John O</creator><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><general>Lippincott, Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>20170601</creationdate><title>Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy: Which Threshold Is the Best Predictor of Local Control?</title><author>Castelli, Joël ; Depeursinge, Adrien ; de Bari, Berardino ; Devillers, Anne ; de Crevoisier, Renaud ; Bourhis, Jean ; Prior, John O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3394-dd7674512343d1427cb825d167c279a7d88850a56f5f0cb39c11380633acd7253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Bioengineering</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18 - metabolism</topic><topic>Glycolysis</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oropharyngeal Neoplasms - diagnostic imaging</topic><topic>Oropharyngeal Neoplasms - metabolism</topic><topic>Oropharyngeal Neoplasms - pathology</topic><topic>Oropharyngeal Neoplasms - radiotherapy</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Positron-Emission Tomography</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Castelli, Joël</creatorcontrib><creatorcontrib>Depeursinge, Adrien</creatorcontrib><creatorcontrib>de Bari, Berardino</creatorcontrib><creatorcontrib>Devillers, Anne</creatorcontrib><creatorcontrib>de Crevoisier, Renaud</creatorcontrib><creatorcontrib>Bourhis, Jean</creatorcontrib><creatorcontrib>Prior, John O</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Clinical nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castelli, Joël</au><au>Depeursinge, Adrien</au><au>de Bari, Berardino</au><au>Devillers, Anne</au><au>de Crevoisier, Renaud</au><au>Bourhis, Jean</au><au>Prior, John O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy: Which Threshold Is the Best Predictor of Local Control?</atitle><jtitle>Clinical nuclear medicine</jtitle><addtitle>Clin Nucl Med</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>42</volume><issue>6</issue><spage>e281</spage><epage>e285</epage><pages>e281-e285</pages><issn>0363-9762</issn><eissn>1536-0229</eissn><abstract>PURPOSEIn the context of oropharyngeal cancer treated with definitive radiotherapy, the aim of this retrospective study was to identify the best threshold value to compute metabolic tumor volume (MTV) and/or total lesion glycolysis to predict local-regional control (LRC) and disease-free survival. METHODSOne hundred twenty patients with a locally advanced oropharyngeal cancer from 2 different institutions treated with definitive radiotherapy underwent FDG PET/CT before treatment. Various MTVs and total lesion glycolysis were defined based on 2 segmentation methods(i) an absolute threshold of SUV (0–20 g/mL) or (ii) a relative threshold for SUVmax (0%–100%). The parameters’ predictive capabilities for disease-free survival and LRC were assessed using the Harrell C-index and Cox regression model. RESULTSRelative thresholds between 40% and 68% and absolute threshold between 5.5 and 7 had a similar predictive value for LRC (C-index = 0.65 and 0.64, respectively). Metabolic tumor volume had a higher predictive value than gross tumor volume (C-index = 0.61) and SUVmax (C-index = 0.54). Metabolic tumor volume computed with a relative threshold of 51% of SUVmax was the best predictor of disease-free survival (hazard ratio, 1.23 [per 10 mL], P = 0.009) and LRC (hazard ratio1.22 [per 10 mL], P = 0.02). CONCLUSIONSThe use of different thresholds within a reasonable range (between 5.5 and 7 for an absolute threshold and between 40% and 68% for a relative threshold) seems to have no major impact on the predictive value of MTV. This parameter may be used to identify patient with a high risk of recurrence and who may benefit from treatment intensification.</abstract><cop>United States</cop><pub>Copyright Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>28288042</pmid><doi>10.1097/RLU.0000000000001614</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0363-9762
ispartof Clinical nuclear medicine, 2017-06, Vol.42 (6), p.e281-e285
issn 0363-9762
1536-0229
language eng
recordid cdi_hal_primary_oai_HAL_hal_01534147v1
source MEDLINE; Journals@Ovid Complete
subjects Adult
Aged
Bioengineering
Disease-Free Survival
Female
Fluorodeoxyglucose F18 - metabolism
Glycolysis
Humans
Life Sciences
Male
Middle Aged
Oropharyngeal Neoplasms - diagnostic imaging
Oropharyngeal Neoplasms - metabolism
Oropharyngeal Neoplasms - pathology
Oropharyngeal Neoplasms - radiotherapy
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Proportional Hazards Models
Retrospective Studies
Tumor Burden
title Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy: Which Threshold Is the Best Predictor of Local Control?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T06%3A58%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20Tumor%20Volume%20and%20Total%20Lesion%20Glycolysis%20in%20Oropharyngeal%20Cancer%20Treated%20With%20Definitive%20Radiotherapy:%20Which%20Threshold%20Is%20the%20Best%20Predictor%20of%20Local%20Control?&rft.jtitle=Clinical%20nuclear%20medicine&rft.au=Castelli,%20Jo%C3%ABl&rft.date=2017-06-01&rft.volume=42&rft.issue=6&rft.spage=e281&rft.epage=e285&rft.pages=e281-e285&rft.issn=0363-9762&rft.eissn=1536-0229&rft_id=info:doi/10.1097/RLU.0000000000001614&rft_dat=%3Cproquest_hal_p%3E1877526678%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1877526678&rft_id=info:pmid/28288042&rfr_iscdi=true